A new approach for how payers reimburse for drugs is gaining traction. Merck (NYSE: MRK) became the latest to jump on board. The drugmaker forged a pay-for-performance deal with Aetna for diabetes drugs Januvia and Janumet. But could this trend wind up costing biotech investors lots of money?
Image source: Getty Images.